These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11859283)

  • 1. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
    Dziankowska-Bartkowiak B; Waszczykowska E; Łuczyńska M; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2005 Aug; 2005(3):144-9. PubMed ID: 16106100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2003 Dec; 12(6):339-43. PubMed ID: 14668093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
    Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
    Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
    Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
    Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.
    Shahin A; Elsawaf A; Ramadan S; Shaker O; Amin M; Taha M
    Mediators Inflamm; 2006; 2006(6):38458. PubMed ID: 17392585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
    Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
    Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
    J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
    Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
    J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
    Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
    Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.
    Andersen GN; Nilsson K; Pourazar J; Hackett TL; Kazzam E; Blomberg A; Waldenström A; Warner J; Rantapää-Dahlqvist S; Mincheva-Nilsson L; Sandström T
    Respir Med; 2007 Oct; 101(10):2199-206. PubMed ID: 17643278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis.
    D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M
    Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.